ICRP (ICRP) Stock Price & Analysis
ICRP (ICRP) rose 0.00% to USD 8.26 as of June 9, 2026 at 23:38 UTC, according to Nexqual real-time market data.
ICRP last closed at USD 8.26; the session ranged USD 11–11 on volume of 1,826 shares. Market capitalization is $83.59M, with a 52-week range of USD 6.5–11 (PNK). Source: Nexqual, June 9, 2026 at 23:38 UTC.
Key Statistics (as of June 9, 2026 at 23:38 UTC)
| Price | USD 8.26 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 8.26 |
| Open | USD 11 |
| Day Range | USD 11 – 11 |
| 52-Week Range | USD 6.5 – 11 |
| Volume | 1,826 shares |
| Market Cap | $83.59M |
| Exchange | PNK |
Technical Analysis (ICRP)
Nexqual's technical model rates ICRP "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 23:38 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 7.62) |
| MACD | 0.26 (positive) |
Analyst Ratings (ICRP)
Wall Street analysts rate ICRP "None", per Nexqual as of June 9, 2026 at 23:38 UTC.
| Consensus Rating | None |
|---|
Earnings (ICRP)
Source: Nexqual, June 9, 2026 at 23:38 UTC.
Financial Health Score (ICRP)
Nexqual rates ICRP's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:38 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Mixed — No data |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
From ICRP's Latest SEC 10-K Filing (filed 2026-03-13)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HXBM | Helix BioMedix, Inc. | USD 1.79 | ▲ 0% |
| HMGN | HEMAGEN DIAGNOSTICS INC | USD 0 | ▲ 0% |
| INIS | Radnostix, Inc. | USD 0.07 | ▲ 3.29% |
| AOLS | AEOLUS PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| BBAL | NEW YORK HEALTH CARE INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:38 UTC. This page is informational and not investment advice.